专利号:US-7211590-B2 优先权日:2002-08-01 标 题:Nitrosated proton pump inhibitors, compositions and methods of use 发明人:FANG XINQIN; GARVEY DAVID S; LETTS L GORDON 权利人:NITROMED INC 摘要:The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.
专利号:US-7256205-B2 优先权日:1998-11-17 标题 :Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 发明人:GARVEY DAVID S; LETTS L GORDON; LIN CHIA-EN; WANG TIANSHENG 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated H 2 receptor antagonist compounds, and novel compositions comprising at least one H 2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H 2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
专利号:US-7332505-B2 优先权日:1999-02-26 标 题 :Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use 发明人:GARVEY DAVID S; LETTS L GORDON; RICHARDSON STEWART K; TAM SANG WILLIAM; WANG TIANSHENG 权利人:NITROMED INC 摘要:The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.
专利号:US-5639987-A 优先权日:1994-11-29 标题:Compositions modifying ballistic properties and propellants containing such compositions 发明人:BERTELEAU GERARD; FONBLANC GILLES; LONGEVIALLE YVES; RAT MAURICETTE 权利人:POUDRES & EXPLOSIFS STE NALE 摘要:The present invention lies in the field of compositions which modify the ballistic properties of solid propellants and in that of the double-base solid propellants containing these compositions. Various lead compounds are known to be effective in this function, but these compounds are toxic; the problem which is solved by the present invention is to replace these lead compounds with nontoxic compounds which furthermore do not impair other properties and the performance values of the propellants. The modifying compounds are chosen from the group consisting of beta -resorcylates and gamma -resorcylates. The invention also relates to processes for the synthesis of some of these products. Finally, it relates to double-base solid propellants containing these compounds.
专利号:RU-2130933-C1 优先权日:1992-10-27 标题 :Derivatives of 4-quinolinyl showing anti-helicobacterial activity, method of their synthesis, pharmaceutical composition containing their and method of its preparing
1: Pitz AM, Park GW, Lee D, Boissy YL, Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93-100. doi: 10.1080/19490976.2015.1008336. 2: Hinostroza Morales D, Díaz Ferrer J. [Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events]. Rev Gastroenterol Peru. 2014 Oct-Dec;34(4):315-20. Spanish. doi: 10.1179/2047773215Y.0000000028. Epub 2015 Aug 11. 4: Bingham AL, Brown RO, Dickerson RN. Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. Nutr Clin Pract. 2013 Dec;28(6):766-9. doi: 10.1177/0884533613507606. Epub 2013 Oct 25. doi: 10.14309/crj.2014.27. eCollection 2014 Apr.